According to a report by Reuters on Wednesday, New Jersey-based Amicus Therapeutics Inc. (NASDAQ:FOLD) announced that in a 24-month trial, its new drug migalastat was effective at reducing abnormal fat accumulation in kidney cells compared with placebo. The drug is being considered alone and in combination therapy for treating Fabry disease, a congenital disorder that can be debilitating and even fatal. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares after opening at $2.33 moved to $2.50 on last trade day and at the end of the day closed at $2.22. Company price to sales ratio in past twelve months was calculated as 345.65 and price to cash ratio as 1.69. Amicus Therapeutics, Inc. (NASDAQ:FOLD) showed a positive weekly performance of 18.09%.
There are larger companies that reported, but Cubist Pharmaceuticals Inc. (NASDAQ:CBST) made the biggest stock move when instead of reporting a 4 cent loss in adjusted earnings per share, it produced a 30 cent gain. As a result, Cubist shares jumped 8% to $67.42 in recent action. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) shares advanced 12.52% in last trading session and ended the day on $70.11. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) yearly performance is 50.22%.
OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) announced Monday morning that the Phase 3 SYNERGY trial testing the combination of custirsen and standard first line docetaxel/prednisone therapy failed to meet the primary end point of the test. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) shares moved up 1.82% in last trading session and was closed at $3.92, while trading in range of $3.85 – $4.25. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) year to date (YTD) performance is -53.00%.
Biota Pharmaceuticals Inc. (NASDAQ:BOTA) said it has been notified by the Department of Health and Human Services of a stop-work order related to a number of activities under its contract for the development of a treatment for two strains of the flu. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) weekly performance is -38.56%. On last trading day company shares ended up $3.68. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) distance from 50-day simple moving average (SMA50) is -39.17%. Analysts mean target price for the company is $7.00.